Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | OAT | P04181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21403880 | 1.00 | SLC1A2 (0.34) | SLC1A2HTR2CGRM2GRM3DPP8 | |
| Trifluoroacetic Acid SCHEMBL21403865 | 1.00 | SLC1A2 (0.34) | SLC1A2HTR2CGRM2GRM3DPP8 | |
| Trifluoroacetic Acid SCHEMBL21403870 | 0.90 | DPP8 (0.33) | SLC1A2HTR2CGRM2GRM3DPP8 | |
| Trifluoroacetic Acid SCHEMBL20241254 | 0.86 | SMYD3 (0.35) | SLC1A2HTR2CDPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL21403856 | 0.86 | SMYD3 (0.35) | SLC1A2HTR2CDPP8DPP7DPP4 | |
| Trifluoroacetic Acid SCHEMBL30599171 | 0.81 | CHRNB2 (0.33) | SLC1A2HTR2C | |
| SCHEMBL15297581 | 0.80 | — | — | |
| SCHEMBL12464408 | 0.80 | — | — | |
| Trifluoroacetic Acid SCHEMBL20241324 | 0.79 | OAT (0.33) | SLC1A2DPP4OAT | |
| Trifluoroacetic Acid SCHEMBL21403917 | 0.79 | OAT (0.33) | SLC1A2DPP4OAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279218-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3551627-B1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190300516-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300516-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | SLC1A2 148/4885HTR2C 459/4885GRM2 55/4885 |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | SLC1A2 148/4885HTR2C 459/4885GRM2 55/4885 |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA1, GABRA3 | SLC1A2 207/4885HTR2C 337/4885GRM2 54/4885 |
| US-20240279218-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | SLC1A2 148/4885HTR2C 459/4885GRM2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.